September 30, 2025 — Leads & Copy — Natera, Inc. (NASDAQ: NTRA) announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology – Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for patients with germ cell tumors (GCT), including testicular cancer.
The study analyzed 324 plasma samples from 74 patients with testicular cancer, across stages I-III, and demonstrated that Signatera-positivity was significantly associated with shorter event-free survival (EFS) in both post-surgical and surveillance settings.
Testicular cancer represents approximately 95% of all GCTs and is the most common malignancy in men aged 15-35. Serum tumor markers (STM) play a central role in the management of testicular cancer, but their utility is limited since they can be normal or falsely elevated in a substantial proportion of patients.
“These findings demonstrate that ctDNA can identify which patients with testicular cancer are at high risk of recurrence or progression,” said Nabil Adra, M.D., associate professor of medicine at Indiana University and principal investigator of the study.
“Testicular cancer is the most common cancer in young men,” said Minetta Liu, M.D., chief medical officer of oncology at Natera. “Serum tumor biomarkers are widely used but often leave gaps in decision-making. These results, which represent the largest published study of ctDNA in testicular cancer to date, highlight the unique value of Signatera to reliably detect molecular residual disease and predict clinical outcomes.”
Contact: Investor Relations, ir@natera.com
Source: Natera
